LAVA Therapeutics NV (FRA:4PKB)
€ 1.61 -0.06 (-3.59%) Market Cap: 43.42 Mil Enterprise Value: -32.23 Mil PE Ratio: 0 PB Ratio: 1.13 GF Score: 49/100

LAVA Therapeutics NV at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 16, 2023 / 06:00PM GMT
Release Date Price: €2.64 (-15.38%)
Daina Graybosch
SVB Securities LLC - Analyst

Good afternoon. Good morning, everyone. My name is Daina Graybosch. I am the analyst here at SVB Securities that covers immuno-oncology companies, and I'm pleased to welcome for a presentation and fireside chat the management team from LAVA. And they're going to start with presentation and then we'll get into Q&A. If you'd like me to pose a question to the management team, there's a question box beneath our faces. Go ahead and type it there. And I will try to weave it in. So that, I'll turn it over to Steve to get us started.

Steve Hurly
LAVA Therapeutics N.V. - CEO & Board Director

Thank you, Daina. And thank you, SVB Securities, for the invitation. And thank you all for those listening online.

My name is Steve Hurly. I'm the CEO of LAVA Therapeutics. It's my pleasure today to introduce you to the company and technology and walk you through some recent clinical data that we have. As a reminder, here's our forward-looking statement. Please review before making any investment decisions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot